{
    "clinical_study": {
        "@rank": "31810", 
        "acronym": "PEMP", 
        "arm_group": {
            "arm_group_label": "Type 2 diabetes subjects newly prescribed Forxiga", 
            "description": "A post-marketing evaluation of the safety of Forxiga (10 mg tablets, orally once daily for 6 months) through an observational prescription adverse event monitoring program (registry-based monitoring program) is warranted to assess real-world incidence of adverse events in routine clinical practice."
        }, 
        "brief_summary": {
            "textblock": "The study purpose is to assess adverse events in patients with Type 2 diabetes who have\n      newly been prescribed Forxiga for the management of glycemic control"
        }, 
        "brief_title": "Forxiga Prescription Event Monitoring Program", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus, Type 2"
        }, 
        "detailed_description": {
            "textblock": "Observational Model: Other: A post-marketing evaluation of the safety of Forxiga through an\n      observational prescription adverse event monitoring program (registry-based monitoring\n      program) is warranted to assess real-world incidence of adverse events in routine clinical\n      practice"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients with Type 2 Diabetes whom the Healthcare professional (HCP) would consider as\n        suitable candidates for Forxiga treatment will be invited to participate in the program\n        during routine clinical assessment\n\n        Inclusion Criteria:\n\n          -  Patients with Type 2 Diabetes who are:\n\n               -  Prescribed Forxiga for glycaemic management AND\n\n               -  Who have the ability to provide informed consent\n\n        Exclusion Criteria:\n\n          -  Patients with whom use of Forxiga is contraindicated:\n\n               -  Patients with Type 1 Diabetes\n\n               -  Patients with moderate to severe renal impairment [Creatinine clearance (CrCl)\n                  <60 mL/min or estimated glomerular filtration rate (eGFR) <60mL/min/1.73m\u00b2]"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Primary care clinic"
            }
        }, 
        "enrollment": {
            "#text": "5000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01944618", 
            "org_study_id": "MB102-209"
        }, 
        "intervention": {
            "arm_group_label": "Type 2 diabetes subjects newly prescribed Forxiga", 
            "intervention_name": "Forxiga", 
            "intervention_type": "Drug", 
            "other_name": "Dapagliflozin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 13, 2013", 
        "number_of_groups": "1", 
        "official_title": "Forxiga (Dapagliflozin Propanediol Monohydrate) Prescription Event Monitoring Program", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Assessed in patients with Type 2 diabetes who are treated with Forxiga in routine Australian clinical practice", 
                "measure": "Incidence rates of adverse events, specifically genital infections, urinary tract infections, increased haematocrit, renal impairment, hepatic impairment, bone fractures and cancers, in particular breast, bladder, and prostate cancers", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Any early adverse effects as a result of drug interactions in patients with Type 2 diabetes who are treated with Forxiga in routine Australian clinical practice", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Incidence rates of spontaneously reported hypoglycaemia in patients with Type 2 diabetes who are treated with Forxiga in routine Australian clinical practice", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01944618"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Rate of prescribing of Forxiga after its introduction to routine Australian clinical practice", 
                "safety_issue": "No", 
                "time_frame": "Upto 6 months"
            }, 
            {
                "measure": "Indication for prescription of Forxiga in routine Australian clinical practice", 
                "safety_issue": "No", 
                "time_frame": "Upto 6 months"
            }, 
            {
                "description": "Including:\nHbA1c\nWeight\nSystolic blood pressure\nDiastolic blood pressure\nHeart rate\nSerum creatinine\nEstimated glomerular filtration rate\nLiver function tests [Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), or bilirubin]", 
                "measure": "Change in efficacy and safety variables after treatment with Forxiga for at least 3 months", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 3 months"
            }, 
            {
                "description": "Subgroups to be evaluated will include gender, age, diabetes duration, concomitant medication, past medical history, and measured laboratory variables (if available)", 
                "measure": "Subgroup analyses may be conducted for selected safety parameters", 
                "safety_issue": "No", 
                "time_frame": "Upto 6 months"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "collaborator": {
                "agency": "Monash University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}